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SUMMARY – Th e aim of the study was to evaluate the possible association between Apo E poly-
morphisms and age at seizure onset in patients with non-lesional temporal lobe epilepsy. Eighty 
 patients with non-lesional temporal lobe epilepsy with or without bilateral tonic-clonic propagation 
were analyzed. Age at seizure onset was defi ned as age at the fi rst unequivocal seizure (excluding 
 febrile convulsions). ApoE alleles were determined by a procedure where genome DNA was amplifi ed 
by chain reaction along with polymerase, using the LightCycler kit (Roche) for ApoE mutations on 
 codons 112 and 158. Th ere was a statistically signifi cant diff erence between the groups of patients with 
ApoE ε2/3 and ε3/4 genotypes (p=0.03), but not between patients with ApoE ε2/3 and ε3/3, and 
those with ApoE ε3/4 and ε3/3. In conclusion, the results of our study suggested positive association 
of a specifi c ApoE genotype and onset of non-lesional temporal lobe epilepsy.
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Introduction
Apolipoprotein E (ApoE) as the main carrier of 
lipids in the brain is thought to be especially important 
for repair mechanisms in the central nervous system 
(CNS)1-3. After neuronal tissue damage, the synthesis 
of the ApoE protein is up-regulated in the reactive 
 astrocytes4,5. However, ApoE isoforms vary in their 
neuroprotective properties6,7. ApoE defi ciency has 
been shown to adversely aff ect outcome after transient 
cerebral ischemia and head trauma. Since oxidative 
stress contributes to these injuries, the ability of ApoE 
to reduce irreversible oxidative damage was studied8,9.
Th e ApoE gene is a confi rmed genetic risk factor 
that infl uences both the risk and age at onset of Alz-
heimer’s disease and Parkinson’s disease10. ApoE is also 
associated with age at onset in some other degenera-
tive neurological diseases11-14.
With the increasing evidence for the role of ApoE 
in repair mechanisms in the brain3, ApoE polymor-
phisms and their link to temporal lobe epilepsy (TLE) 
has attracted ever more attention15,16. It is therefore 
possible that some developmental or childhood brain 
injury has occurred in a person with ApoE ε4, and 
there may be a failure to repair the damage, resulting in 
an epileptogenic lesion.
Based on pathological data derived from temporal 
lobe specimens of patients with TLE, ApoE may well 
be accepted as one of the susceptibility genes, a marker 
to identify people at risk of early or delayed onset of 
developing epilepsy. ApoE ε4 genotype is associated 
with an earlier onset of chronic TLE17, but some other 
studies were not able to fi nd a link between TLE, on-
set of disease and ApoE polymorphism18-20.
Th e aim of this study was to evaluate the associa-
tion between ApoE polymorphism and age at onset in 
patients with non-lesional TLE.
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Patients and Methods
Patients
In this study, 80 patients with non-lesional TLE 
with or without bilateral tonic-clonic propagation 
were analyzed during a six-year period (2006-2012). 
Th e study was conducted at Zagreb University Hospi-
tal Center and Dubrava University Hospital in Za-
greb. Diagnosis of TLE was based on clinical history, 
seizure semiology and interictal electroencephalo-
graphic (EEG) monitoring. Age at seizure onset was 
the age of the subject at the fi rst unequivocal seizure 
(excluding febrile convulsions) as determined retro-
spectively after having collected all available informa-
tion. TLE was classifi ed as non-lesional if no epilepto-
genic foreign-tissue lesion was detected on brain mag-
netic resonance imaging (MRI; epilepsy protocol, 
power 1.5T). Demographic and basic characteristics of 
study groups are shown in Table 1. Th e inclusion crite-
ria were adult subject diagnosed with non-lesional 
TLE with or without secondarily generalized seizures 
lasting for at least three years. Subjects with a history 
of CNS infection, head trauma, brain tumor, cerebro-
centrifuged, the cells were separated from the liquid 
blood phase, and both fractions were deeply frozen. 
Purifi cation of DNA from blood was done with a 
commercial BioSprint 15 DNA Blood Kit (Qiagen, 
Germantown, USA). ApoE alleles were determined by 
a procedure where genome DNA was amplifi ed by 
chain reaction along with polymerase, using the Light-
Cycler kit (Roche, Mannheim, Germany) for ApoE 
mutations on codons 112 and 158.
Statistics
Microsoft SPSS statistical package for Windows, 
version 10.0 was used. Results were expressed as mean 
value and standard deviation (SD). Diff erences be-
tween the groups were tested by analysis of variance 
(ANOVA) and post-hoc Tukey test. Th e p-value of 
<0.05 was considered statistically signifi cant.
Th e study was approved by the local ethics com-
mittee, and all patients signed the informed consent 
form to take part in the study.
Results
Distribution of the alleles in patients with non-le-
sional TLE was as follows: ε2/3 in seven (8.75%) pa-Table 1. Demographic and basic characteristics of study 
groups




Age, mean (SD) 40.01 (SD 13.28)




Positive genetic loading 9 (11.25)
Febrile convulsions 13 (16.25)
Perinatal accident 8 (10.00)
Partial complex seizures 31 (38.75)
Secondary generalization 49 (61.25)
vascular lesion, pseudoattacks, neurodegenerative and 
psychiatric disease, hippocampal sclerosis, cortical dys-
plasia and nonprogressive tumors and perinatal hypox-
ic-ischemic encephalopathy were excluded.
Genotyping
Blood samples for determination of ApoE geno-
type were obtained from all patients. Th e sample was 
Th ere was a statistically signifi cant diff erence between the groups 
of patients with ApoE ε2/3 and ε3/4 genotype (p=0.03), but not 
between patients with ApoE ε2/3 and ε3/3, and those with Apo E 
ε3/4 and ε3/3. Diff erences between the groups were tested by anal-
ysis of variance (ANOVA) and post-hoc Tukey test. Th e p-value of 
<0.05 was considered statistically signifi cant.
Fig. 1. Age at onset of temporal lobe seizure and ApoE 
genotype polymorphism.
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tients, ε3/3 in 57 (71.25%) patients and ε3/4 in 16 
(20.00%) patients. Th ere were no patients with ApoE 
2/2, 2/4, and 4/4 genotypes.
Th e average age at onset of temporal lobe seizure 
was 24±11 years in patients with ApoE ε2/3 genotype, 
14±8 in patients with ApoE ε3/4 genotype, and 18±9 
years in those with ApoE ε3/3 genotype. Th ere was a 
statistically signifi cant diff erence between the groups 
of patients with ApoE ε2/3 and ε3/4 genotypes 
(p=0.03), but not between the patients with ApoE 
ε2/3 and ε3/3 genotypes, and those with ApoE ε3/4 
and ε3/3 genotypes (Fig. 1).
Discussion
Study results showed that patients with non-le-
sional TLE and Apo E ε2/3 genotype had a statisti-
cally signifi cantly delayed onset of disease as compared 
to patients with ApoE ε3/4 genotype. Patients with 
ApoE ε3/3 genotype also had the average age at onset 
of disease four years later than patients with Apo E 
ε3/4 genotype and six years earlier than patients with 
ApoE ε2/3, but diff erence between these groups of pa-
tients did not reach statistical signifi cance. A small 
sample size might be one of the reasons for this. Th e 
frequency of ApoE alleles among our subjects was 
similar to that reported in healthy European popula-
tion. Th e results may suggest an association of ApoE 
ε2 and recovery/plasticity of the cell membrane, but 
may also support the possible neuroprotective role of 
ApoE ε2 genotype in patients with delayed onset of 
disease and less protective role of ApoE ε4 genotype in 
patients with earlier onset of disease.
Our results are consistent with those reported from 
the study by Briellmann et al., where apoE ε4 allele 
was associated with an earlier onset of TLE17. Patients 
with e4 allele had the average age at onset of disease 
ten years earlier than patients without e4 allele. More-
over, as the majority of patients had an early childhood 
lesion, these fi ndings suggest that ApoE e4 allele may 
have an important eff ect on determining the length of 
the silent interval. In contrast to this, there was no dif-
ference in the age at onset of epilepsy in patients with 
focal seizures with copy of the e2, e3 or e4 allele in 
studies by Kilpatric et al.18 and Blumke et al.19. Th e 
same result has been reported by Yeni et al.20 in a group 
of patients suff ering from mesial temporal lobe epilep-
sy-hippocampal sclerosis, and by Kauff man et al.21.
Th e neuroprotective properties of ApoE isoforms 
were investigated in several experimental studies on 
cell cultures and on mice. ApoE ε2 and ApoE ε3, in 
contrast to ApoE ε4, enhance neuronal growth and 
increase resistance of cell cultures to oxidative stress22. 
Th e presence of recombinant human ApoE ε2 in pri-
mary mixed neuronal-glial cell cultures partially pro-
tected against oxidative injury by reducing secondary 
glutamate excitotoxicity23. Furthermore, ApoE defi -
cient mice are more prone to oxidative tissue damage 
after ischemia than mice with normal ApoE produc-
tion8. Similarly, transgenic mice with the ApoE ε3/3 
genotype have a better neurological outcome and sur-
vival rate after ischemic and oxidative stress than mice 
with the ApoE ε4/4 genotype9,24. Th ese results clearly 
indicate a neuroprotective eff ect of Apo E by preserv-
ing the integrity of neuronal membranes, with ApoE 
ε/ApoE ε2 being more eff ective than Apo E ε4.
Th e neuroprotective role of ApoE polymorphism 
and oxidative stress caused by free radicals were also 
investigated in some other chronic degenerative neu-
rological diseases. Th e epsilon 4 allele of the ApoE 
gene has been consistently associated with an earlier 
onset of Alzheimer’s and Parkinson’s disease10,25,26. Th e 
ApoE e4 allele seems to predispose carriers with mul-
tiple sclerosis to faster progression of the disease13. In 
Wilson’s disease, the ApoE genotype was established 
as an important factor delaying the onset of neuro-
logical and hepatic symptoms14. Th e presence of Apo 
E e3/3 attenuates clinical manifestation by a mecha-
nism that may involve the antioxidant and membrane-
stabilizing properties of the ApoE ε3 protein, while 
the onset of symptoms was signifi cantly delayed in 
patients with the ApoE ε3/4 genotype. ApoE ε2 is 
protective against earlier onset of amyotrophic lateral 
sclerosis with an average age at onset in ApoE ε2 car-
riers approximately 3 years later than in non-ApoE ε2 
carriers11.
In conclusion, results of our study suggest that 
polymorphism of ApoE genotype might be a marker 
that is associated with the onset of disease in patients 
with non-lesional TLE.
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Sažetak
POVEZANOST APOLIPOPROTEINA E ε2 
S KASNIJIM POČETKOM EPILEPSIJE TEMPORALNOG REŽNJA
D. Sporiš, S. Bašić, J. Sertić, D. Mahović Lakušić i T. Babić
Cilj ovoga istraživanja bio je utvrditi moguću povezanost genskog polimorfi zma ApoE s dobno ranijim početkom bolesti 
kod bolesnika s epilepsijom temporalnog režnja i negativnim nalazom magnetske rezonancije mozga. U istraživanje je bilo 
uključeno 80 bolesnika s epilepsijom temporalnog režnja i negativnim nalazom magnetske rezonancije mozga. Dob početka 
bolesti defi nirana je kao dob pojavnosti prvog neprovociranog epilepsijskog napadaja (isključujući febrilne konvulzije). ApoE 
aleli su određeni postupkom pri kojem je genomska DNA amplifi cirana lančanom reakcijom uz polimerazu, a korišten je 
detekcijski kit LightCycler (Roche) za mutacije ApoE na kodomu 112 i 158. Utvrđena je značajna statistička razlika između 
skupina bolesnika s genotipom ApoE ε2/3 i ε3/4 (p=0,03), dok između bolesnika s ApoE ε2/3 i ε3/3 i onih s ApoE ε3/4 i 
ε3/3 nije bilo značajne statističke razlike. Rezultati istraživanja ukazuju na moguću povezanost specifi čnog genotipa ApoE i 
dobi početka bolesti kod bolesnika s epilepsijom temporalnog režnja i negativnim nalazom magnetske rezonancije mozga.
Ključne riječi: Apolipoprotein E2; Polimorfi zam, genetski; Epilepsija temporalnog režnja; Dob pojave bolesti
